Lupin receives US FDA approval for Cephalexin capsules

By Our Corporate Bureau | 01 Dec 2005

1

Lupin Ltd has received US FDA approval for its abbreviated new drug application (ANDA) for Cephalexin capsules USP 250mg and 500mg. The US market for Cephalexin Capsules is estimated at $80 million.

This is the Lupin''s eighth ANDA approval by the US FDA till date and the third in this financial year. Earlier this year, the company had received approvals from the US FDA for Lisinopril tablets and Cephalexin for oral suspension. The approval makes Company one of the select few integrated players who offer both Cephalexin capsules and suspension in the US market.

A main stay cephalosporin antibiotic, Cephalexin is indicated for the treatment of respiratory tract infections caused by S.pneumoniae and S.pyogenes, skin and skin structure infections caused by staphylococci and/or streptococci. bone infections caused by staphylococci and / or P. mirabilis and genitourinary tract infections, including acute prostatitis, caused by E. coli, P. mirabilis and K. pneumoniae.

Business History Videos

History of hovercraft Part 3...

Today I shall talk a bit more about the military plans for ...

By Kiron Kasbekar | Presenter: Kiron Kasbekar

History of hovercraft Part 2...

In this episode of our history of hovercraft, we shall exam...

By Kiron Kasbekar | Presenter: Kiron Kasbekar

History of Hovercraft Part 1...

If you’ve been a James Bond movie fan, you may recall seein...

By Kiron Kasbekar | Presenter: Kiron Kasbekar

History of Trams in India | ...

The video I am presenting to you is based on a script writt...

By Aniket Gupta | Presenter: Sheetal Gaikwad

view more